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Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase
(IDO1) is an important mechanism of peripheral immune tolerance
contributing to tumoral immune resistance, and IDO1 inhibition is
an active area of drug development. Tryptophan 2,3-dioxygenase
(TDO) is an unrelated hepatic enzyme that also degrades trypto-
phan along the kynurenine pathway. Here, we show that enzy-
matically active TDO is expressed in a significant proportion of
human tumors. In a preclinical model, TDO expression by tumors
prevented their rejection by immunized mice. We developed a
TDO inhibitor, which, upon systemic treatment, restored the ability
of mice to reject TDO-expressing tumors. Our results describe
a mechanism of tumoral immune resistance based on TDO expres-
sion and establish proof-of-concept for the use of TDO inhibitors in
cancer therapy.
cancer immunotherapy | small molecule inhibitor | immunomodulation |
immune suppression
Tryptophan 2,3-dioxygenase (TDO) is a homotetrameric heme-containing cytosolic enzyme encoded by gene TDO2 and ex-
pressed at high levels in the liver. It catalyses the first and rate-
limiting step of tryptophan degradation along the kynurenine
pathway and thereby regulates systemic tryptophan levels. The
same reaction can be catalyzed by another heme-containing cy-
tosolic enzyme, named indoleamine 2,3-dioxygenase (IDO1),
which has no sequence similarity with TDO, is not expressed in
the liver, and is monomeric. IDO1 has been the focus of attention
in recent years because of its immunosuppressive effects on T
lymphocytes, resulting partly from tryptophan depletion and
partly from direct effects of tryptophan catabolites (1–3). IDO1 is
expressed constitutively in the placenta, where it plays a key role
in feto-maternal tolerance (2), and in many tumors, where it
contributes to tumoral resistance to immune rejection (4–7).
IDO1 expression is also inducible in many cells, including den-
dritic cells, and appears to play a role in peripheral immune tol-
erance and the retro-control of immune responses (8). In contrast,
little is known about the effect of TDO expression on the immune
response. A recent report indicated that human cells transfected
with TDO depleted tryptophan and thereby prevented both the
growth of pathogens and the proliferation of allogeneic T lym-
phocytes (9). These results suggested that TDO might mediate
immunosuppressive effects similar to those of IDO1. We set out
to examine whether tumor cells express TDO and thereby inhibit
T-cell–mediated immune responses.
Results
We first observed that many human tumor samples expressed
gene TDO2 as measured by real-time RT-PCR (Table 1). This
was the case for 41% of bladder carcinomas, 50% of melanomas
and 100% of hepatocarcinomas. To confirm the activity of TDO
in tumor cells, we selected a series of human tumor cell lines that
also expressed the TDO2 mRNA. We incubated cells for 24 h in
medium containing a known concentration of tryptophan, and
measured by HPLC in the supernatant the concentration of
tryptophan and kynurenine, which is the main tryptophan ca-
tabolite (Table 2). HEK-293 cells transfected or not with human
TDO2 were used as positive and negative controls. We observed
a clear activity in cell lines expressing more than one copy of
TDO2 mRNA per cell. Because some of these tumor lines also
expressed IDO1, we used TDO inhibitor 680C91 (10) and IDO1
inhibitor 1-methyl-L-tryptophan (1MT) (4) to distinguish the
activity of both enzymes in the cellular assay. In cell lines
expressing TDO and not IDO1, tryptophan degradation was
completely blocked by 680C91 and not by 1MT, as expected
(Table 2). In cell lines expressing both enzymes, an additive ef-
fect of both inhibitors was observed (Table 2 and Fig. S1). The
TDO activity of those lines and its direct inhibition by 680C91
were confirmed in an enzymatic assay performed on crude cell
extracts, which is not dependent on the transport of the substrate
and the inhibitor across the cell membrane (Table 2 and Fig. S2).
To determine whether TDO expression allows tumor cells to
resist immune rejection by T cells, we used the P815 mouse tu-
mor model (4). P815 tumor cells regularly produce tumors when
injected intraperitoneally into naïve syngeneic DBA/2 mice, even
though they are clearly immunogenic and express several tumor
antigens recognized by cytolytic T lymphocytes (CTL). One of
these antigens is encoded by cancer germ-line gene P1A and is
the major target of the rejection response of mice immunized
against P815 (11). Mice immunized against this antigen reject
a challenge of P815 tumor cells injected in the peritoneal cavity
(12). We transfected subline P815B, which does not express
TDO2, with an expression plasmid containing the mouse TDO2
cDNA. We selected transfected P815B mTDO clones 8 and 12,
which degraded tryptophan at levels similar to human tumor
lines (Table 2). We then immunized mice against the P1A an-
tigen and injected them 4 wk later with an i.p. challenge of
transfected P815 cells. As expected, most mice rejected the
control P815B clone 1, which was transfected with an empty
vector and did not express TDO (Fig. 1A). In contrast, most mice
injected with TDO-expressing tumor cells developed progressive
tumors and died. This was true for both TDO-transfected clones.
The three clones produced progressive tumors in all naïve mice,
but the TDO-expressing tumors grew somewhat faster (Fig. 1B).
This might result from the occurrence of a primary immune re-
sponse that retards the growth of the tumors and is abolished
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with the TDO-expressing tumors. The intrinsic tumorigenicity of
the three clones was similar, as indicated by their identical pro-
gression in irradiated mice (Fig. 1B). They also expressed iden-
tical levels of P1A mRNA, as measured by semiquantitative RT-
PCR, and were equally lysed by P1A-specific CTL (Fig. 1C).
These results were very similar to those we reported previously
with IDO1-expressing tumor cells, and suggested that the pro-
gression of TDO-expressing tumors in P1A-immunized mice
resulted from the ability of those tumors to prevent their re-
jection by T lymphocytes. To visualize this effect on T lympho-
cytes, we used H-2Ld/P1A tetramers to measure the number of
P1A-specific CTL in the peritoneal cavity of immunized mice
before and after the challenge with P815 tumor cells. Immunized
mice contained detectable amounts of P1A-specific CTL, which
further increased four days after challenge with P815B control
cells (Fig. 1D). This increase was limited in mice challenged with
TDO-expressing P815B mTDO cl12, suggesting that TDO ex-
pression reduces T lymphocyte proliferation locally.
The results outlined above indicated that pharmacological
inhibition of TDO could combat tumoral immune resistance and
promote tumor rejection. So far, several compounds were reported
as TDO inhibitors (10, 13–15). One series, initially developed by
Madge and Salter as combined TDO/serotonin reuptake inhibitors
for depression therapy, is characterized by a (fluoro)indole scaffold
substituted in the 3-position by a pyridinyl-vinyl side chain. Among
these compounds, the analog 680C91 represents a very attracting
compound, as it is endowed with a good TDO inhibition potency
and is deprived of activity on serotonin reuptake (10). As a first
step, we assessed bioavailability of 680C91 inmice by the oral route.
After administration of 160 mg/kg/day in the drinking water up to
7 d, wemeasured plasma concentrations of 680C91 below 0.2 μg/mL
(0.8 μM), indicating the poor bioavailability of the compound,
presumably related to its poor solubility (Fig. 2A). We thus started
a medicinal chemistry program aimed at improving the aqueous
solubility and bioavailability in this series (16). This eventually led to
the discovery of compound LM10, which is characterized by a 6-
fluoro-indole substituted in the 3-position by a tetrazolyl-vinyl side
chain and displays a good TDO inhibition (Ki = 5.6 μM) with
a competitive inhibition profile (Fig. 2A; ref. 16). LM10 does not
inhibit IDO and has a high solubility and bioavailability (Fig. 2A).
The plasma concentration of LM10 after oral administration of 160
mg/kg/day was between 20 and 40 μg/mL (87-175 μM), a concen-
tration about 40 times above the IC50measured in the cellular assay
performed with the physiological concentration of plasma trypto-
phan (80 μM; Fig. 2A; ref. 17).
To determine whether systemic treatment with LM10 was able
to promote rejection of TDO-expressing tumors, we immunized
and challenged mice as above and administered LM10 in the
drinking water (Fig. 2B). We observed that systemic treatment of
immunized mice with LM10 (160 mg/kg/day) prevented the
growth of TDO-expressing P815 tumor cells. This was true for
both TDO-transfected clones. Surprisingly, LM10 treatment also
promoted better rejection of control clone P815B cl1, which does
not express TDO. One explanation for this might be the ex-
pression of TDO by macrophages at the tumor site, as activation
of macrophages by phorbol esters or intracellular infection was
shown to induce TDO expression (18, 19). We confirmed ex-
pression of TDO2 mRNA in F4/80+ macrophages isolated from
the peritoneal cavity of both control mice and immunized mice
carrying ascitic P815B cl1 tumor cells (Fig. S3).
Mice treated with LM10 did not show obvious signs of toxicity.
Because TDO is mostly expressed in the liver, we evaluated liver
damage at the end of the experiment as a first attempt to eval-
uate the safety of LM10 treatment. After more than 100 d of
systemic administration of LM10, we found no significant dif-
ference between treated and untreated mice for their plasma
level of hepatic enzymes alkaline phosphatase (ALAP), γ-glu-
tamyltransferase (γ-GT), alanine aminotransferase (ALAT), and
aspartate aminotransferase (ASAT) (Table 3). Those levels
remained within the normal range, suggesting the lack of liver
toxicity of prolonged TDO inhibition with LM10.
To determine whether the antitumor effects of LM10 resulted
only from promoting tumor rejection or whether LM10 also had
a direct effect on tumor cells, we injected immunodeficient
RAG2 knockout mice with TDO-expressing P815 cells and
treated them with LM10 as above. Tumor growth was not af-
fected by LM10 treatment in RAG2 knockout mice, indicating
that the effect of LM10 was dependent on the immune system in
this model (Fig. 3).
Discussion
Cancer immunotherapy is emerging as a promising approach for
cancer treatment. Various strategies to modulate antitumor
responses have been tested for many years and some of them
recently proved clinically useful or even gained FDA approval
(20–26). However, it is also becoming clear that an important
limitation of cancer immunotherapy results from the ability of
some tumors to resist immune rejection (27). A variety of
mechanisms can account for such resistance, only some of which
are amenable to modulation to improve the efficacy of cancer
immunotherapy. One such mechanism is based on tryptophan
catabolism by IDO1, which is frequently expressed in tumors (4,
6). We previously observed in a preclinical model that rejection
of IDO1-expressing tumors was promoted by systemic treatment
with an IDO1 inhibitor (4). The search for IDO1 inhibitors that
can be used clinically is ongoing (7, 28–30). We show here that
tumors also use another means to degrade tryptophan and resist
immune rejection: they express TDO, the tryptophan-degrading
enzyme normally expressed almost exclusively in the liver. In-
terestingly, the immunosuppressive effect of liver-expressed
TDO might contribute to the allograft tolerance usually ob-
served after liver transplantation, as recently suggested (9).
Table 1. TDO2 expression in human samples
TDO2-positive
samples
(no. positive/
no. tested)
TDO2 mRNA/cell in
positive samples
Sample type Mean Min–max
Tumors
Bladder carcinoma 9/22 23.7 (2.6–125)
Hepatocarcinoma 7/7 791.7 (47.4–4,000)
Melanoma 10/20 5.6 (2.0–16.7)
Mesothelioma 2/4 8.5 (2.4–14.6)
Neuroblastoma 2/3 5.2 (2.1–8.4)
Sarcoma 1/5 5.9 (5.9)
Breast carcinoma 2/17 12.2 (7.8–16.7)
Leukemia 1/25 16.7 (16.7)
Renal cell carcinoma 1/7 88.4 (88.4)
Colorectal carcinoma 2/7 9.2 (4.8–13.6)
Head & neck
carcinoma
1/9 9.0 (9.0)
Lung carcinoma 2/8 11.4 (3.6–19.2)
Brain tumor 2/10 4.7 (4.2–5.3)
Normal tissues
Liver 3/3 876.3 (406.1–1515.7)
Skin 0/2 0.0 (0.0)
Bladder 0/2 0.1 (0.05–0.2)
Breast 0/3 0.1 (0.0–0.1)
Blood 0/2 0.0 (0.0)
Expression of TDO2mRNAwasmeasuredby quantitative RT-PCR. Each cDNA
was performed at least in duplicate. TDO2 expression was normalized to actin
and the amount of mRNA molecules per cell was calculated. Tumor samples
containing at least two molecules of TDO2 mRNA per cell were considered
positive. For normal tissues, means and min-max are provided for all samples.
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Similarly, low levels of TDO were observed in early concepti,
where they might contribute to tolerance of the embryo by the
maternal immune system (31–33).
Using a TDO inhibitor, we proved, in a preclinical model, the
concept that TDO inhibition promotes tumoral immune rejection.
It will be of interest to evaluate the role of TDO in additional tumor
models expressing various levels of TDO. The adverse effects of
TDO inhibition appear limited. TDO is normally expressed at
a high level in the liver and at low level in the brain (34).We did not
observe obvious toxicity in mice treated with LM10 for 3 months.
Moreover, mice genetically deficient for TDO2 were recently
obtained and found viable and healthy (35). The main observation
Table 2. TDO expression and activity in tumor cell lines
TDO2 mRNA/cell* IDO1 mRNA/cell*
Kynurenine production (pmol kynurenine/hr/106 cells)
Cellular assay†
Assay on crude
extract‡
Inhibitor - 680C91 1MT 680C91+1MT - 680C91
Human cell lines
293-E 0.0 0.0 0 0 0
293-E hTDO cl105 993.1 0.0 2,462 0 2,051 0 1,111 (±13) 61 (±9)
293-E hTDO cl119 1,231.1 0.0 3,743 94 3,333 105 544 (±14) 15 (±3)
HepG2 (hepatocarcinoma) 0.0 0.0 0 0 0 0
Huh7 (hepatocarcinoma) 1.9 0.0 41 0 0 0
LB159-CRC (colorectal carcinoma) 67.0 0.0 2,007 0 1,869 0
SK-CO-11 (colorectal carcinoma) 0.5 0.0 0 0 0 0
LB1317-SCCHN (head & neck carcinoma) 58.3 19.2 2,973 715 2,310 303 3,252 (±14) 277 (±19)
A172 (glioblastoma) 31.2 1.6 3,753 119 3,775 0 708 (±7) 18 (±5)
HTZ-349 (glioblastoma) 0.1 0.0 0 0 0 0
U-87-MG (astrocytoma) 8.7 0.0 413 0 559 0
SK-Mes-1 (lung carcinoma) 6.3 0.4 1,117 926 515 354
LB2259-MEL (melanoma) 0.1 0.0 0 0 0 0
MZ2-MEL (melanoma) 0.3 0.0 0 0 0 0
MZ-CHA-3 (gall-bladder carcinoma) 4.5 35.9 534 366 217 144
Murine cell lines
Mastocytoma P815, subline P815B 0.0 0.0 ND ND
Transfected P815B cells:
P815B cl1 (control) 0.0 0.0 0 0 0
P815B mTDO cl8 129.6 0.0 4,857 103 2,330 (±32) 55 (±5)
P815B mTDO cl12 166.8 0.0 5,483 136 4,090 (±24) 128 (±8)
*Expression of human or mouse TDO2 and IDO1 mRNA was measured by quantitative RT-PCR, normalized to actin and expressed as the amount of mRNA
molecules per cell. Each cDNA was tested at least in duplicate.
†Enzymatic activity was estimated by measuring tryptophan degradation and kynurenine production in the supernatant of 14-h (murine lines) or 24-h (human
lines) cultures performed in the absence or presence of TDO inhibitor 680C91 (20 μM), IDO1 inhibitor 1-methyl-L-tryptophan (1MT, 400 μM) or both.
Tryptophan and kynurenine were measured by HPLC. ND, not determined.
‡Enzymatic activity (± SEM) was estimated by measuring kynurenine production in the clarified cell extracts with L-tryptophan at 1 mM in the absence or
presence of TDO inhibitor 680C91 (25 μM). The rate of catalysis was calculated within the linear phase of N-formylkynurenine production. Results are the
mean value of three independent experiments performed in duplicate and with two measures for each duplicate.
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Fig. 1. Immune resistance of TDO-expressing tumors. (A) Mice (n = 45 per group) were immunized by i.p. injection of living L1210 cells expressing P1A and
B7-1, and challenged 4 wk later by i.p. injection of 4 × 105 cells either P815B cl1 (○), or P815B-mTDO cl8 (◇), or P815B-mTDO cl12 (●). Tumor progression was
monitored. Shown are the compiled results of three experiments, each involving groups of 15 mice. P < 0.001 for cl1 versus cl8 and for cl1 versus cl12 (Logrank
test). (B) Naïve (solid line) (n = 15 per group) or irradiated mice (dashed line) (n = 5 per group, 650 cGy) were injected as in A. One representative experiment
out of five is shown. (C) Lysis of TDO-transfected P815B cells by P1A-specific CTLs. P1A-specific CTLs were incubated with 51Cr-loaded TDO-transfected P815B
cells at varying effector/target ratios. P815 variant P1.istA-B-, which has lost gene P1A, was used as a control target (□) P1A-negative variant). One repre-
sentative experiment out of three is shown. (D) Proportion of P1A-specific T cells among CD8+ T cells in the peritoneal cavity of immunized mice, estimated
using H-2Ld/P1A tetramers 1 d before or 4 d after i.p. challenge with 106 cells of P815B cl1 (○, n = 30 mice) or P815B-mTDO cl12 (●, n = 30 mice). Error bars
represent SEM. P < 0.001 for cl1 versus cl12 after challenge (two-tailed Student t test). One representative experiment out of two is shown.
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in those mice is a reduced anxiety, which may result from their
highly increased serum levels of tryptophan. Indeed, tryptophan is
the precursor of serotonin, and TDO inhibitors were previously
considered as potential antidepressants (10).
A recent report published during the reviewing process of this
paper corroborates our findings by showing that TDO is ex-
pressed constitutively in human glioblastomas and promotes
tumor progression through the production of kynurenine acting
as endogenous ligand of the aryl hydrocarbon receptor, resulting
in increased tumor cell survival and motility, and reduced anti-
tumor immune responses (36). In our tumor model, however, we
did not observe a tumor cell autonomous effect of TDO activity,
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Fig. 2. Reversal of immune resistance by systemic inhibition of TDO. (A) Structure, activity, physicochemical features, and bioavailability of TDO inhibitors
680C91 and LM10. Ki were measured on recombinant human TDO (hTDO) (16). A cellular assay based on mouse P815B-mTDO, mouse P815B-mIDO, or human
293E-hTDO cells was used tomeasure IC50, defined as the concentration giving 50% inhibition of TDOactivity at a L-tryptophan concentration of 80 μM.Values±
SEMare shown corresponding to themean of three independent experiments. LD50was estimated by anMTT assay evaluating cell viability in the same cultures.
Solubility was evaluated at room temperature as described in ref. 16. Bioavailability was estimated by measuring plasma concentration of the compounds after
1, 2, or 7 d of oral administration of 160 mg/kg/day. Mice (n = 10) received either normal drinking water or a solution of 1 mg/mL 680C91 at pH 2.5 or 1 mg/mL
LM10 at pH 9, ofwhich they drank an averageof 4mL/day. (B) Tumor progression in immunizedmice (n = 45 per group) challenged by i.p. injection of 4× 105 cells
from either P815B-mTDO cl8 (diamonds, Left), P815B-mTDO cl12 (triangles, Center), or P815B cl1 (circles, Right) and treated (black symbol) or not (white symbol)
with 160mg/kg/day LM10 in the drinkingwater, starting one day before the injection of tumor cells. Shown are the compiled results of three experiments, each
involving groups of 15 mice. The untreated groups are identical to those shown on Fig. 1A. Mice received either normal drinking water or a solution of LM10 at
1 mg/mL P = 0.001, P < 0.001, and P = 0.006 for treated versus untreated mice after challenge with cl8, cl12 and cl1, respectively (Logrank test).
Table 3. Evaluation of liver toxicity of LM10 in mice
Liver enzyme* ALAT (IU/mL ± SEM) ALAP (IU/mL ± SEM) ASAT (IU/mL ± SEM) γ-GT (IU/mL ± SEM)
Control† 34.8 ± 2.4 74.4 ± 2.3 106.7 ± 8.8 3.0 ± 0.2
LM10-treated‡ 47.5 ± 3.3 92.7 ± 3.0 156.9 ± 8.1 2.8 ± 0.2
Normal range§ 21–83 68–89 70–215 1–4
*Enzyme activities were measured in the plasma. ALAP: alkaline phosphatase; γ-GT: γ-glutamyl transferase;
ALAT: alanine aminotransferase, ASAT: aspartate aminotransferase.
†Group of 43 mice from the experiment reported in Fig. 2B, fed with normal drinking water and tested 107
d after tumor challenge. Shown are the compiled results of three independent assays.
‡Group of 82 mice from the experiment reported in Fig. 2B, fed with a solution of LM10 (1 mg/mL pH 9; 160 mg/
kg/day) and tested 107 d after tumor challenge. Shown are the compiled results of three independent assays.
§Group of 7 untreated normal DBA/2 mice.
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as TDO inhibition in vivo resulted in tumor control in immune
competent but not in immunodeficient mice (Fig. 3).
Blocking both TDO and IDO1 to improve the efficacy of cancer
immunotherapy would be complementary, not redundant: in a se-
ries of 104 human tumor lines of various histological types, we
observed 20 tumors expressing only TDO2, 17 expressing only IDO1
and 16 expressing both (Table 4). Therefore, targeting both IDO1
and TDO would allow reaching 51% of tumors instead of 32% with
IDO1 or 35% with TDO alone. Moreover, our results suggest that
TDO inhibition might be useful also for tumors that do not in-
trinsically express TDO. If confirmed, this notion would further
increase the proportion of tumors eligible for such a therapy.
In conclusion, pharmacological inhibition of TDO might
represent a safe and efficient approach for cancer therapy acting
by promoting tumoral immune rejection, thereby leveraging
cancer immunotherapy.
Materials and Methods
Mice. DBA/2 mice aged 6–8 wk were purchased from Harlan, provided food and
water ad libitum, and housed under specific pathogen-free conditions. Animals
were immunized by injection of 106 live L1210.P1A.B7-1 cells into the peritoneal
cavity and challenged 4 wk later by i.p. injection of 4 × 105 tumor cells, as de-
scribed (4, 12). As indicated, mice were given LM10 in the drinking water (1 mg/
mL, pH 9), of which they drank an average of 4 mL/day. For assessment of bio-
availability, naïvemice (n=10)were given a solution of 680C91 (1mg/mL, pH 2.5)
or LM10 (1mg/mL, pH 9) instead of drinkingwater. Bloodwas collected from the
retro-orbital sinus in Lithium-Heparin tubes (Microvette 500 LH, Sarstedt). After
centrifugation at 11,000 × g for 10 min, plasma was collected and the concen-
tration of compound was measured by HPLC-UV at 345 nm (680C91) or 326 nm
(LM10). For the HPLC analysis, 50 μl of supernatant were mixed with 500 μl of
acetonitrile toprecipitate theproteins.After centrifugation, the supernatantwas
collected, concentrated in a speedvac, resuspended in a final volume of 100 μl of
water, and injectedonto anOnyxMonolithic C18 column (Phenomenex). Hepatic
enzymeswere assayed on a Synchron CX system according to themanufacturer’s
instructions (BeckmanCoulter). The ethical committeeof the Faculty ofMedicine,
Université Catholique de Louvain, approved all mouse experiments.
Further Details. See SI Materials and Methods for details about:
- Cell lines and tumor samples
- Cellular assay for TDO and IDO activity
- Enzymatic assay for TDO activity on crude extracts
Tu
m
or
 v
ol
um
e 
(m
m3
)
%
 m
ice
 w
ith
 tu
m
or
 p
ro
gr
es
sio
n
P815B mTDO cl8
0
125
250
375
500
625
0 4 8 12 16 20 24
Days after tumor injection
0
20
40
60
80
100
0 4 8 12 16 20 24
Days after tumor injection
P815B mTDO cl8 + LM10
0
0 4 8 12 16 20 24
Days after tumor injection
0
20
40
60
80
100
0 4 8 12 16 20 24
Days after tumor injection
125
250
375
500
625
P815B mTDO cl12
P815B mTDO cl12 + LM10
0
0 4 8 12 16 20 24
Days after tumor injection
0
20
40
60
80
100
0 8 12 16 20 24
Days after tumor injection
125
250
375
500
625
4
P815B cl1
P815B cl1 + LM10
A
B
Fig. 3. Lack of antitumor effect of
LM10 in RAG2 knockout mice. RAG2
knockout mice (15 per group) re-
ceived a s.c. injection of 2 × 105 cells
of the indicated P815 tumor clones
(either P815B-mTDO cl8 (diamonds,
Left), P815B-mTDO cl12 (triangles,
Center), or P815B cl1 (circles, Right),
and were treated (filled symbols) or
not (open symbols) with 160 mg/kg/
day LM10 in the drinking water (1
mg/mL) as in Fig. 2. The proportion
of mice bearing progressive tumors
in A and the mean tumor volume in
B are reported. Tumor volume was
calculated with formula (π x L x l2)/
12. One representative experiment
is shown out of two.
Table 4. TDO2 and IDO1 expression in human tumor cell lines
Tumor type TDO2 only IDO1 only TDO2 and IDO1 Total
Colorectal carcinoma 5/11 1/11 0/11 6/11
Glioblastoma 1/8 3/8 1/8 5/8
Leukemia 1/4 0/4 0/4 1/4
Lymphoma 0/4 0/4 0/4 0/4
Melanoma 0/12 2/12 0/12 2/12
Mesothelioma 1/7 2/7 3/7 6/7
Myeloma 1/3 0/3 0/3 1/3
Head and neck
carcinoma
1/11 2/11 5/11 8/11
Ovarian carcinoma 0/1 1/1 0/1 1/1
Pancreatic
adenocarcinoma
0/5 3/5 1/5 4/5
NSCLC 5/7 0/7 1/7 6/7
SCLC 0/6 0/6 0/6 0/6
Sarcoma 0/6 0/6 2/6 2/6
Breast carcinoma 1/4 1/4 0/4 2/4
Bladder carcinoma 0/3 1/3 2/3 3/3
Hepatocarcinoma 0/2 0/2 0/2 0/2
Gall-bladder carcinoma 0/1 0/1 1/1 1/1
Renal cell carcinoma 4/9 1/9 0/9 5/9
Total 20/104 17/104 16/104 53/104
Expression of TDO2 an IDO1was evaluated by RT-PCR on RNA isolated from
human tumor cell lines. NSCLC: non small cell lung carcinoma, SCLC: small cell
lung carcinoma. In some tumor types, such as melanoma, the proportion of
TDO2-expressing tumor lines is lower than the proportion of TDO2-expressing
tumor samples (see Table 1). Two factors may explain this difference: (i) during
establishment of the cell lines, TDO-expressing tumor cellsmay havebeen coun-
terselected because of their tryptophan-depleting effect, as in most cases the
cell lines were established in the absence of TDO inhibitor, and (ii) TDO might
also be expressed by some stromal cells, such as activated macrophages, which
are present in tumor samples and absent in tumor cell lines.
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- Lysis assay
- Tetramer staining and fluorescence-activated cell sorting analysis
- Quantitative RT-PCR analysis of mRNA expression
- Cellular assay for TDO inhibition
- Compounds synthesis and characterization
- Synthesis of trans-3-(6-fluoro-1H-indol-3-yl)acrylonitrile
- Synthesis of trans-6-Fluoro-3-[2-(1H-tetrazol-5-yl)vinyl]-1H-indole (LM10)
- Statistics.
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